$CLNN Balance Sheet | Understand Stock

$CLNN

$3.97 +$0.13 (3.39%) Close

$CLNN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets:
Cash
Cash and cash equivalents
Marketable securities
Accounts receivable
Inventory
Prepaid expenses and other current assets
Metals to be used in research and development
Total current assets
Restricted cash
Operating lease right-of-use assets
Property and equipment, net
TOTAL ASSETS

Current liabilities:
Accounts payable
Accrued liabilities
Income tax payable
Deferred revenue from related parties
Share subscriptions payable
Operating lease obligations, current portion
Finance lease obligations, current portion
Clene Nanomedicine contingent earn-out, current portion
Notes payable, current portion
Convertible notes payable, current portion
Total current liabilities
Operating lease obligations, net of current portion
Finance lease obligations, net of current portion
Notes payable, net of current portion
Deferred income tax
Warrant liability
Common stock warrant liability
Convertible notes payable, net of current portion
Derivative liabilities
Common Stock Warrant Liability
Derivatives Other Than Common Stock Warrants Liabilities
Total derivative liabilities
Clene Nanomedicine contingent earn-out liability
Initial Stockholders contingent earn-out liability
TOTAL LIABILITIES

Stockholders’ deficit:
Common stock, $0.0001 par value: 600,000,000 shares authorized; 12,778,307 and 10,849,974 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
TOTAL STOCKHOLDERS’ DEFICIT
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

Comments